These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35125232)

  • 21. Idursulfase in Hunter syndrome treatment.
    Zareba G
    Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.
    Żuber Z; Różdżyńska-Świątkowska A; Jurecka A; Tylki-Szymańska A
    PLoS One; 2014; 9(1):e85074. PubMed ID: 24454794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry.
    Racoma MJC; Calibag MKKB; Cordero CP; Abacan MAR; Chiong MAD
    Orphanet J Rare Dis; 2021 Jul; 16(1):323. PubMed ID: 34289859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
    Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
    Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl.
    Semyachkina AN; Voskoboeva EY; Zakharova EY; Nikolaeva EA; Kanivets IV; Kolotii AD; Baydakova GV; Kharabadze MN; Kuramagomedova RG; Melnikova NV
    BMC Med Genet; 2019 May; 20(1):66. PubMed ID: 31046699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution.
    Manara R; Rampazzo A; Cananzi M; Salviati L; Mardari R; Drigo P; Tomanin R; Gasparotto N; Priante E; Scarpa M
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S67-72. PubMed ID: 20052546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical practice guideline for the management of Hunter syndrome. Hunter España working group].
    Guillén-Navarro E; Blasco AJ; Gutierrez-Solana LG; Couce ML; Cancho-Candela R; Lázaro P;
    Med Clin (Barc); 2013 Nov; 141(10):453.e1-13. PubMed ID: 24060500
    [No Abstract]   [Full Text] [Related]  

  • 28. Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome.
    Julien DC; Woolgar K; Pollard L; Miller H; Desai A; Lindstrom K; Kishnani PS
    Front Immunol; 2020; 11():1000. PubMed ID: 32508845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cervical spine MRI findings in patients with Mucopolysaccharidosis type II.
    Żuber Z; Jurecka A; Jurkiewicz E; Kieć-Wilk B; Tylki-Szymańska A
    Pediatr Neurosurg; 2015; 50(1):26-30. PubMed ID: 25721852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective analysis of the clinical manifestations and survival of Korean patients with mucopolysaccharidosis type II: emphasis on the cardiovascular complication and mortality cases.
    Sohn YB; Choi EW; Kim SJ; Park SW; Kim SH; Cho SY; Jeong SI; Huh J; Kang IS; Lee HJ; Paik KH; Jin DK
    Am J Med Genet A; 2012 Jan; 158A(1):90-6. PubMed ID: 22105882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
    Christianto A; Watanabe H; Nakajima T; Inazu T
    Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.
    Marín LL; Gutiérrez-Solana LG; Fernández AT
    Pediatr Dermatol; 2012; 29(3):369-70. PubMed ID: 21995841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
    Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
    Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resolution of Hydronephrosis in a Patient With Mucopolysaccharidosis Type II With Enzyme Replacement Therapy.
    Nishiyama K; Imai T; Ohkubo K; Sanefuji M; Takada H
    Urology; 2017 Mar; 101():163-165. PubMed ID: 28011272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.
    Muenzer J; Lamsa JC; Garcia A; Dacosta J; Garcia J; Treco DA
    Acta Paediatr Suppl; 2002; 91(439):98-9. PubMed ID: 12572850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome.
    Dalmau Serra J; Vitoria Miñana I; Calderón Fernández R; Cortell Aznar I
    Med Clin (Barc); 2015 Nov; 145(9):392-8. PubMed ID: 26360015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.
    Muenzer J; Jones SA; Tylki-Szymańska A; Harmatz P; Mendelsohn NJ; Guffon N; Giugliani R; Burton BK; Scarpa M; Beck M; Jangelind Y; Hernberg-Stahl E; Larsen MP; Pulles T; Whiteman DAH
    Orphanet J Rare Dis; 2017 May; 12(1):82. PubMed ID: 28464912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed.
    Al Sawaf S; Mayatepek E; Hoffmann B
    J Inherit Metab Dis; 2008 Aug; 31(4):473-80. PubMed ID: 18618289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.